Advertisement

Epidemiology of Brain Tumors

  • Randa El-Zein
  • Melissa Bondy
  • Margaret Wrensch
Part of the Contemporary Cancer Research book series (CCR)

Abstract

Brain cancer accounts for approx 1.4% of all cancers and 2.3% of all cancer-related deaths. The incidence of primary cerebral malignancies varies between 4 and 10/100,000 in the general population. This incidence tends to increase with age (4/100,000 up to the age of 12 yr; 6/100,000 up to the age of 35 yr; 18/100,000 up to the age of 55 yr; 70/100,000 up to the age of 75 yr).

Keywords

Epidermal Growth Factor Receptor Familial Adenomatous Polyposis Basal Cell Carcinoma Tuberous Sclerosis Primary Brain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Airewele G.E., Sigurdson A.J., Wiley K.J., Frieden B.E., Caldarera L.W., Riccardi V.M., et al. 2001. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet. Epidemiol. 20:75–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Altermatt H.J., Shepherd C.W., Scheitauer B.W., and Gomez M.R. 1991. Subependymal giant cell astrocytoma. Zentralbl. Pathol. 137:105–116.PubMedGoogle Scholar
  3. 3.
    American Cancer Society 2002. Cancer Facts and Figures. American Cancer Society, Inc.Google Scholar
  4. 4.
    Bello M.J., De Campos J.M., Kusak M.E., Sarasa J.L., Saez-Castresana J., Pestana A., et al. 1994. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int. J. Cancer 57:172–175.PubMedCrossRefGoogle Scholar
  5. 5.
    Bernard S.M., Cartwright R.A., Darwin C.M. et al. 1987. Hodgkin’s disease: case control epidemiological study in Yorkshire. Br. J. Cancer 55:85–90.PubMedGoogle Scholar
  6. 6.
    Biernat W., Tohma Y., Yonekawa Y., Kleihues P., Ohgaki H. 1997. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta. Neuropathol. 94:303–309.PubMedCrossRefGoogle Scholar
  7. 7.
    Bigner S.H., Mark J., Burger P.C., Mahaley M.S., Bullard D.E., Muhlbaier L.H., et al. 1988. Specific chromosomal abnormalities in malignant gliomas. Cancer Res. 88:405–411.Google Scholar
  8. 8.
    Blatt J., Jaffee R., Deutsch M., et al. 1986. Neurofibromatosis and childhood tumors. Cancer 57:1225–1229.PubMedCrossRefGoogle Scholar
  9. 9.
    Bodmer W.F., Bailey C.J., Ellis A., et al. 1987. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328:614–616.PubMedCrossRefGoogle Scholar
  10. 10.
    Bondy M., Ligon B.L. 1996. Epidemiology and etiology of intracranial meningiomas: a review. J. Neurooncol. 29:197–205.PubMedCrossRefGoogle Scholar
  11. 11.
    Bondy M., Wiencke J., Wrensch, M., Kyritsis, A.P. 1994. Genetics of primary brain tumors: a review. J. Neurooncol. 18:69–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Bondy M.L, Kryitsis A.P., Gu J., de Andrade M., Cunningham J., Levin V.A., et al. 1996. Mutagen sensitivity and risk of gliomas: a case-control study. Cancer Res. 56:1484–1486.PubMedGoogle Scholar
  13. 13.
    Bondy M.L., Lustbader E.D., Buffler P.A. et al. 1991. Genetic epidemiology of childhood brain tumors. Genet. Epidemiol. 8:253–267.PubMedCrossRefGoogle Scholar
  14. 14.
    Bondy M.L., Wang, L.E., El-Zein R., de Andrade, M., Selvan, M.S., Bruner, J.M., et al. 2001. Gamma-radiation sensitivity and risk of glioma. J. Natl. Cancer Inst. 93:1553–1557.PubMedCrossRefGoogle Scholar
  15. 15.
    Brauch H., Kishida T., Glavac D., Chen F., Pausch F., Hofler H., et al. 1995. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet. 95:551–556.PubMedCrossRefGoogle Scholar
  16. 16.
    Buckley J.D., Buckley C.M., Breslow N.E., Draper G.J., Roberson P.K., Mack T.M. 1996. Concordance for childhood cancer in twins. Med. Pediatr.Oncol. 26:223–229.PubMedCrossRefGoogle Scholar
  17. 17.
    Burch, J.D., Craib, K.J., Choi, B.C., Miller, A.B., Risch, H.A., Howe, G.R. 1987. An exploratory case-control study of brain tumors in adults. J. Natl. Cancer. Inst. 78:601–609.PubMedGoogle Scholar
  18. 18.
    Burk R.R. 1991. Von Hippel-Lindau disease angiomatosis of the retina and cerebellum. J. Am. Optometry Assoc. 62:382–385.Google Scholar
  19. 19.
    Busch D. 1994. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int. J. Rad. Oncol. Biol. Phys. 30:997–1002.Google Scholar
  20. 20.
    Caggana M., Kilgallen J., Conroy J.M., Wiencke J.K., Kelysey K.T., Mike, R., Chen P., et al. 2001. Associations Between ERCC2 Polymorphisms and Gliomas. Cancer Epidemiology, Biomarkers and Prevention 10:355–360.PubMedGoogle Scholar
  21. 21.
    Cheadle J.P., Reeve M.P., Sampson J.R., Kwiatkowski D.J., Cheadle J.P., Reeve M.P., Sampson J.R., et al. 2000. Hum. Genet. 107:97–114.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen P., Wiencke J., Aldape K., Kesler-Diaz A., Miike, R., Kelsey K., et al. 2000. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 9:843–847.PubMedGoogle Scholar
  23. 23.
    Choi N.W., Schuman L.M., Gullen W.H. 1970. Epidemiology of primary central nervous system neoplasms. II. Casecontrol study. Am. J. Epidemiol. 91:467–485.PubMedGoogle Scholar
  24. 24.
    Chowdhary U.P., Boehme D.H., Al-Jishi M. 1985. Turcot syndrome glioma polyposis. J. Neurosurg. 63:804–807.PubMedGoogle Scholar
  25. 25.
    Costa O.L., Silva D.M., Colnago F.A., et al. 1987. Turcot Syndrome autosomal dominant or recessive transmission? Dis. Colon Rectum 30:391–394.PubMedCrossRefGoogle Scholar
  26. 26.
    Crossey P.A., Foster K., Richards F.M., Phipps M.E., Latif F., Tory K., et al. 1994. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum. Genet. 93:53–58.PubMedCrossRefGoogle Scholar
  27. 27.
    Crowe F.W., Schull W.J., Neel J.V. 1956. A Clinical, Pathological, and Genetic Study of Multiple Neurofibromatosis. Charles C. Thomas, Springfield, IL.Google Scholar
  28. 28.
    de Andrade, M., Barnholtz, J.S., Amos, C.I., Adatto, P., Spencer, C., Bondy, M.L. 2001. Segregation analysis of cancer in families of glioma patients. Genet. Epidemiol. 20:258–270.PubMedCrossRefGoogle Scholar
  29. 29.
    Dietrich P.Y., Droz J.P., 1992. Renal cell cancer: Oncogenes and tumor suppressor genes. Rev. Pract. 42:1236–1240.Google Scholar
  30. 30.
    Doneda L., Ginelli E., Agresti A., Larizza L. 1989. In situ hybridization analysis of interstitial C-heterochromatin in marker chromosomes of two human melanomas. Cancer Res. 49:433–438.PubMedGoogle Scholar
  31. 31.
    Draper G.J., Heaf M.M., Kinnier Wilson LM. 1977. Occurrence of childhood cancers among sibs and estimation of familial risks. J. Med. Genet. 14:81–90.PubMedGoogle Scholar
  32. 32.
    El-Zein R., Bondy M.L., Wang L.E., de Andrade M., Sigurdson A.J., Bruner J.M., et al. 1999. Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. Carcinogenesis. 20: 811–815.PubMedCrossRefGoogle Scholar
  33. 33.
    Elexpuru-Camiruaga, J., Buxton, N., Kandula, V., Dias P.S., Campbell, D., McIntosh, J., et al. 1995. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione-S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res. 55:4237–4239.PubMedGoogle Scholar
  34. 34.
    Farndon P.A., Del Mastro R.G., Evans D.G., Kilpatick M.W. 1992. Location of gene for Gorlin syndrome. Lancet 339:581,582.PubMedCrossRefGoogle Scholar
  35. 35.
    Farwell J. and Flannery J.T. 1984. Cancer in relatives of children with central nervous system neoplasms. N. Engl. J. Med. 311:749–753.PubMedCrossRefGoogle Scholar
  36. 36.
    Farwell, J.R., Dohrmann, G.J., Flannery, J.T. 1984. Medulloblastoma in childhood: an epidemiological study. J. Neurosurg. 61:657–664.PubMedGoogle Scholar
  37. 37.
    Fults D., Tippets R.H., Thomas G.A., Nakamura Y., White R. 1989. Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma. Cancer Res. 49:6572–6577.PubMedGoogle Scholar
  38. 38.
    Gailani M.R., Bale S.J., Leffell D.J., et al. 1992. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromsome 9. Cell 69:111–117.PubMedCrossRefGoogle Scholar
  39. 39.
    Gao, L., Liu, L., van Meyel, D., Cairncross, G., Forsyth, P., Kimmel, D., Jenkins, R.B., Lassam, N.J., Hogg, D. 1997. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma. Clin. Cancer Res. 3:977–981.PubMedGoogle Scholar
  40. 40.
    Gold E.B. Epidemiology of brain tumors. 1980. Reviews in Cancer Epidemiology 1:245–254.Google Scholar
  41. 41.
    Gomez MR. Tuberous Sclerosis. Raven Press, New York, 1988.Google Scholar
  42. 42.
    Gorlin RJ. 1987. Nevoid basal cell carcinoma syndrome. Medicine 66:98–113.PubMedCrossRefGoogle Scholar
  43. 43.
    Grosovsky A.J., Parks K.K., Giver C.R., Nelson S.L. 1996. Clonal analysis of delayed karyotypic abnormalities and gene mutations in radiation-induced genetic instability. Mol. Cell Biol. 16: 6252–6262.PubMedGoogle Scholar
  44. 44.
    Grossman S.A., Osman M., Hruban R., and Piantadosi S. 1999. Central nervous system cancers in first-degree relatives and spouse. Cancer Investigation 17:299–308.PubMedGoogle Scholar
  45. 45.
    Haines J.L., Short M.P., Kwiatkowski D.J., et al. 1991. Localization of one gene for tuberous sclerosis within 9q32-9q34, and further evidence for heterogeneity. Am. J. Hum. Genet. 49:764–772.PubMedGoogle Scholar
  46. 46.
    Harvald B., Hauge M. 1956. On the heredity of glioblastoma. J⋁20Natl Cancer Inst. 17:289–296.Google Scholar
  47. 47.
    Hass-Kogan D.A., Kogan S.S., Yount G., Hsu J., Haas M., Deen D.F., Israel M.A. 1999. P53 function influences the effect of fractionated raditherapy on glioblastoma tumors. Int. J. Radiat. Oncol. Biol. Phys. 43:399–403.CrossRefGoogle Scholar
  48. 48.
    Hemminki K., Li, Vaittinen X., Dong P., 2000. Cancers in the first degree relatives of children with brain tumors. Br. J. Cancer 83:407–411.PubMedCrossRefGoogle Scholar
  49. 49.
    Hill J.R., Kuriyama N., Kuriyama H., Israel M.A. 1999. Molecular genetics of brain tumors. Arch. Neurol. 56:439–441.PubMedCrossRefGoogle Scholar
  50. 50.
    Hittelman W.N., Sen P. Heterogeneity in chromosome damage and repair rates after bleomycin in ataxia telangiectasia cells. Cancer Res. 48:276–279.Google Scholar
  51. 51.
    Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K, Marie Y, Sanson M. 2002. OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol. Appl. Neurobiol. 28:89–94.PubMedCrossRefGoogle Scholar
  52. 52.
    Hoang-Xuan K., He J., Huguet S., Mokhtari K., Marie Y., Kujas M., et al. 2001. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278–1281.PubMedGoogle Scholar
  53. 53.
    Hope D.G., Mulvihill J.J. 1981. Malignancy in neurofibromatosis, in Advances in Neurology Vol 29: Neurofibromatosis von Reckinghausen Disease (Riccardi V.M., Mulvihill J.J., eds.). Raven Press, New York.Google Scholar
  54. 54.
    Hsu T.C., Johnston D.A., Cherry L.M., Ramkisson D., Schantz S.P., Jessup J.M., et al. 1989. Sensitivity to genotoxic effect of bleomycin in humans: possible relationship to environmental carcinogenesis. Int. J. Cancer 43:403–409.PubMedCrossRefGoogle Scholar
  55. 55.
    Hunter S.B., Abbot K., Varma V.A., Olson J.J., Barnett D.W., James C.D. 1995. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissues. J. Neuropathol. Exp. Neurol. 54:57–64.PubMedGoogle Scholar
  56. 56.
    Ichimura K., Schmidt E.E., Miyakawa A., Goike H.M., Collins V.P. 1998. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22:9–15.PubMedCrossRefGoogle Scholar
  57. 57.
    Jadayel D., Fain P., Upadhyaya M., et al. 1990. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 343:558.PubMedCrossRefGoogle Scholar
  58. 58.
    Jones A.C., Shyamsundar M.M., Thomas M.W., Maynard J., Idziaszczyk S., Tomkins S., et al. 1999. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64:1305–1315.PubMedCrossRefGoogle Scholar
  59. 59.
    Kapp J.P., Paulson G.W., Odom G.L. 1967. Brain tumors with tuberous sclerosis. J. Neurosurg. 26:191.PubMedGoogle Scholar
  60. 60.
    Kelsey K.T., Wrensch M., Zuo Z.F., Miike R., Wiencke J.K. 1997. A population-based case-control study of the CYP2D6 and GSTT1 polymorphisms and malignant brain tumors. Pharmacogenetics 7:463–468.PubMedCrossRefGoogle Scholar
  61. 61.
    Kleihues P., Ohgaki H. 2000. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicologic Pathology 28:164–170.PubMedGoogle Scholar
  62. 62.
    Kleihues P., Soylememzoglu F., Schauble B., et al. 1995. Histopathology, classification and grading of gliomas. Glio. 15:211–221CrossRefGoogle Scholar
  63. 63.
    Koch G. 1972. Genetic aspects of phacomatoses, in Handbook of Clinical Neurology, Vol. 14 (Vinken P.G., Bruyn G.W., eds.). North Holland, Amsterdam.Google Scholar
  64. 64.
    Kuijten R.R., Bunin G.R., Nass C.C., et al. 1990. Gestational and familial risk factors for childhood astrocytoma: results of a case-control study. Cancer Res. 50:2608–2612.PubMedGoogle Scholar
  65. 65.
    Kyritsis A.P., Bondy M.L., Xiao M., Berman E.L. Cunningham J.E., Lee P.S., et al. 1994. Germline p53 gene mutations in subsets of glioma patients [see comments]. J. Natl. Cancer Inst. 86:344–349.PubMedCrossRefGoogle Scholar
  66. 66.
    Larizza L., Doneda L., Ginelli E., Fossati G. 1988. C-heterochromatin vartiation and transposition in tumor progression, in Cancer Metastasis: Biological and Biochemical Mechanisms and Clinical Aspects (Gprodi et al. eds.), Plenum Publishing Corp., NY, pp. 309–318.Google Scholar
  67. 67.
    Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320.PubMedCrossRefGoogle Scholar
  68. 68.
    Lengauer, C., Kinzler, K.W., Vogelstein, B. 1997. Genetic instability in colorectal cancers. Nature 386:623–627.PubMedCrossRefGoogle Scholar
  69. 69.
    Levine C., Skimming J., Levine E. 1992. Familial pheochromocytomas with unusual associations. J. Pediatr. Surg. 27:447–451.PubMedCrossRefGoogle Scholar
  70. 70.
    Lewis J.H., Ginsberg A.L., Toomey K.E. 1983. Turcot’s syndrome: evidence for autosomal dominant inheritance. Cancer 51:524–528.PubMedCrossRefGoogle Scholar
  71. 71.
    Li F.P., Fraumeni J.F. Jr. 1982. Prospective study of a family syndrome. J. Am. Med. Assoc. 247:2692–2694.CrossRefGoogle Scholar
  72. 72.
    Li F.P., and Fraumeni J.F., Jr. 1975. Soft tissue, breast cancer and other neoplasms. Ann. Int. Med. 83:833,834.PubMedGoogle Scholar
  73. 73.
    Li F.P., Fraumeni J.F. Jr. 1969. tissue sarcoma, breast cancer, and other neoplasms. A family syndrome? Ann. Int. Med. 71:747–752.PubMedGoogle Scholar
  74. 74.
    Li F.P., Fraumeni J.F. Jr, Mulvihill J.J., et al. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48:5358–5362.PubMedGoogle Scholar
  75. 75.
    Li Y, Millikan, R.C., Carozza, S., Newman, B., Liu, E., Davis, R., Miike, R., Wrensch, M. 1998. p53 mutations in malignant gliomas. Cancer Epidemiol., Biomarkers and Prevention 7:303–308.Google Scholar
  76. 76.
    Lynch H.T., Guirgis H.A., Lynch P.M. et al. 1977. Familial cancer syndromes. A survey. Cancer 39:1867–1881.PubMedCrossRefGoogle Scholar
  77. 77.
    Lynch H.T., Lynch J.F. 1985. Genetics and colorectal cancer, in Familial Cancer (Muller H., Weber W., eds.), Karger, Basel, Switzerland, p. 72.Google Scholar
  78. 78.
    Magnani I., Guerneri S., Pollo B., Cirenei N., Colombo B.M., Broggie G., et al. 1994. Increasing complexity of the karyotype in 50 human gliomas: Progressive evolution and de novo occurrence of cytogenetic alterations. Cancer Genet. Cytogenet. 75:77–89.PubMedCrossRefGoogle Scholar
  79. 79.
    Malkin D., Li F.P., Strong L.C., et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcoma, and other neoplasms. Science 250:1233–1238.PubMedCrossRefGoogle Scholar
  80. 80.
    Malmer B., Gronberg, H., Bergenheim, A.T., Lenner, P., Henriksson, R. 1999. Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study. Int. J. Cancer 81:366–370.PubMedCrossRefGoogle Scholar
  81. 81.
    Malmer B., Iselius, L., Holmberg, E., Collins, A., Henriksson, R., Gronberg, H. 2001. Genetic epidemiology of glioma. Br. J. Cancer 84:429–434.PubMedCrossRefGoogle Scholar
  82. 82.
    Marti-Bonmati L., Menor F., Poyatos C., Cortina H. 1992. Diagnosis of Sturge Weber syndrome: comparison of the efficacy of CT and MR imaging in 14 cases. J. Roentgenol. 158:867.Google Scholar
  83. 83.
    Martuza R.L., Eldridge R. 1988. Neurofibromatosis 2: bilateral acoustic neurofibromatosis. N. Engl. J. Med. 318:684.PubMedCrossRefGoogle Scholar
  84. 84.
    McCarthy B.J., Surawicz T., Bruner J.M., Kruchko C., Davis F. 2002. Consensus Conference on Brain Tumor Definition for registration. November 10, 2000. Neurooncol 2:134–145.Google Scholar
  85. 85.
    McKinley B.P., Michalek A.M., Fenstermaker R.A., Plunkett R.J. 2000. The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J. Neurosurg. 93:932–939.PubMedCrossRefGoogle Scholar
  86. 86.
    Mohapatra, G., Kim D.H., Feuerstein B.G. 1995. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer 13:86–93.PubMedCrossRefGoogle Scholar
  87. 87.
    Miller R.W. 1971. Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960-67. J. Natl. Cancer Inst. 46:203–209.PubMedGoogle Scholar
  88. 88.
    Mulcahy G.M., Harlan W.L. 1976. Occurrences of central nervous system tumors, with special reference to relative genetic factors, in Cancer Genetics. (Lynch H.T. ed.), Thomas Books, Springfield, IL.Google Scholar
  89. 89.
    Nichols K.E., Malkin D., Garber, J.E., Fraumeni, J.F., Jr., Li, F.P. 2001. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10: 83–87.PubMedGoogle Scholar
  90. 90.
    Norris F.D., Jackson E.W. 1970. Childhood cancer deaths in California born twins—a further report on types of cancer found. Cancer 25:212–218.PubMedCrossRefGoogle Scholar
  91. 91.
    O’Brien J.M. 2000. Environmental and heritable factors in the causation of cancer—analysis of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343:78–85.CrossRefGoogle Scholar
  92. 92.
    Parry L., Maynard J.H., Patel A., Hodges A.K., von Deimling A., Sampson J.R., et al. 2000. Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Hum. Genet. 4:350–356.CrossRefGoogle Scholar
  93. 93.
    Peters E.S., Kelsey K.T., Wiencke J.K., Park S., Chen P., Miike R., Wrensch, M.R. 2001. NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiology, Biomarkers and Prevention 10: 151–152.PubMedGoogle Scholar
  94. 94.
    Preston-Martin S., Mack W., Henderson B.E. 1989. Risk factors for gliomas and meningiomas in males in Los Angeles County. Cancer Res. 49:6137–6143.PubMedGoogle Scholar
  95. 95.
    Riccardi V.M. 1981. Von Recklinghausen neurofibromatosis. N. Engl. J. Med. 305:1617–1627.PubMedCrossRefGoogle Scholar
  96. 96.
    Richards F.M., Payne S.J., Zbar B., Affara N.A., Ferguson-Smith M.A., Maher ER. 1995. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum. Mol. Genet. 11:2139–2143.CrossRefGoogle Scholar
  97. 97.
    Ritland S.R., Ganju. V, Jenkins R.B. 1995. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12:277–282.PubMedCrossRefGoogle Scholar
  98. 98.
    Rosso S.M., Van Dekken H., Krishnadath K.K., Alers J.C., Kros J.M. 1997. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. J. Neuropathol Exp. Neurol. 56:1125–1131.PubMedCrossRefGoogle Scholar
  99. 99.
    Rubenstein A.E. Neurofibromatosis: a review of the clinical problem. 1986. Ann. NY Acad. Sci. 486:1–13.PubMedCrossRefGoogle Scholar
  100. 100.
    Ryan P., Lee M.W., North B., McMichael A.J. 1992. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Intl. J. Cancer 51:20–27.CrossRefGoogle Scholar
  101. 101.
    Scheil S., Bruderlein S., Liehr T., Starke H., Herms J., Schulte M., Moller P. 2001. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 3:203–211.CrossRefGoogle Scholar
  102. 102.
    Seizinger B.R., Smith D.I., Filling-Katz M.R., et al. 1991. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel Lindau disease. Proc. Natl. Acad. Sci. USA 88:2864–2868.PubMedCrossRefGoogle Scholar
  103. 103.
    Shepherd C.W., Gomez M.R., Lie J.T., Crowson C.S. 1991. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 66:792–796.PubMedGoogle Scholar
  104. 104.
    Shepherd C.W., Scheithauer B.W., Gomez M.R., et al. 1991. Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery 28:864–868.PubMedCrossRefGoogle Scholar
  105. 105.
    Sonoda Y., Iizuka M., Yasuda J., Makino R., Ono T., Kayama T., Yoshimoto T., Sekiya T. 1995. Loss of heterozygosity at 11p15 in malignant gliomas. Cancer Res. 55:2166–2168.PubMedGoogle Scholar
  106. 106.
    Sorenson S.A., Mulvihill J.J., Nielson A., et al. 1986. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl. J. Med. 314:1010–1015.CrossRefGoogle Scholar
  107. 107.
    Smith L.E., Grosovsky A.J. 1993. Genetic instability on chromosome 16 in a B lymphoblastoid cell line. Somat. Cell Mol. Genet. 19:515–527.PubMedCrossRefGoogle Scholar
  108. 108.
    Spitz M.R., McPherson R.S., Jiang H., Hsu T.C., Trizna Z,. Lee J.J., et al. 1997. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol. Biomarkers Prev. 6: 687–692.PubMedGoogle Scholar
  109. 109.
    Stolle C., Glenn G., Zbar B., Humphrey J.S., Choyke P., Walther M., et al.. 1998. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12:417–423.PubMedCrossRefGoogle Scholar
  110. 110.
    Surawicz T.S., McCarthy B.J., Kupelian V., Jukich P.J., Bruner J.M., Davis, F.G. 1999. Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994. Neurooncol. 1:14–25.Google Scholar
  111. 111.
    Tijssen C.C. 1985. Genetic aspects of brain tumors—tumors of neuroepithelial and meningeal tissue, in Familial Cancer (Muller H, Weber W eds.) Karger, Basel, Switzerland.Google Scholar
  112. 112.
    Tijssen C.C., Halprin M.R., Endtz L.J. 1982. Familial Brain Tumours. A Commented Register. Martinus Nijhoff, Boston, MA.Google Scholar
  113. 113.
    The European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305–1315.Google Scholar
  114. 114.
    Trizna, Z., de Andrade, M., Kyritsis, A.P., Briggs, K., Levin, V.A., Bruner, J.M., et al. 1998. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol. Biomarkers Prev. 7:553–555.PubMedGoogle Scholar
  115. 115.
    Ueki K., Ono Y., Henson J.W., Efird J.T., von Deimling A., Louis D.N. 1996. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversly correlated. Cancer Res. 56: 150–153.PubMedGoogle Scholar
  116. 116.
    van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805–808.PubMedCrossRefGoogle Scholar
  117. 117.
    Vieregge P., Gerhard L., and Nahser HC. 1987. Familial glioma: occurrence within the “familial cancer syndrome” and systemic malformations. J. Neurol. 234:220–232.PubMedCrossRefGoogle Scholar
  118. 118.
    von Deimling A., Krone W., and Menon A.G. 1995. Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol. 5:153–162.Google Scholar
  119. 119.
    Wei Q., Spitz M.R., Gu J., Cheng L., Xu X., Strom S.S., et al. 1996. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol. Biomarkers Prev. 5:199–204.PubMedGoogle Scholar
  120. 120.
    Weinberg RA. 1991. Oncogenes, tumor suppressor genes, and cell transformation: trying to put it all together, in Origins of Human Cancer. (Brugge J., Curran T., Harlow E. et al. (eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.Google Scholar
  121. 121.
    Wernicke C., Thiel G., Lozanova T., Vogel S., and Witkowski R. 1997. Numerical aberrations of chromosomes 1,2 and 7 in astrocytomas studied by interphase cytogenetics. Genes Chromosomes Cancer 19:6–13.PubMedCrossRefGoogle Scholar
  122. 122.
    Wolff R.K., Frazer K.A., Jackler R.K., et al. 1992. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors. Am. J. Hum. Genet. 51:478–485.PubMedGoogle Scholar
  123. 123.
    Wrensch M., Lee M., Miike R., Newman B., Barger G., Davis R., Wiencke J., and Neuhaus J. 1997. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. American Journal of Epidemiology 145:581–593.PubMedGoogle Scholar
  124. 124.
    Wrensch M.R., Barger G.R. 1990. Familial factors associated with malignant gliomas. Genet. Epidemiol. 7:291–301.PubMedCrossRefGoogle Scholar
  125. 125.
    Yamakawa K., Morita R., and Takahashi E., et al. 1991. A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res. 51:4707–4711.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Randa El-Zein
    • 1
  • Melissa Bondy
    • 1
  • Margaret Wrensch
    • 2
  1. 1.Department of EpidemiologyThe University of Texas M. D. Anderson Cancer CenterHouston
  2. 2.Department of Epidemiology and Biostatistics, School of MedicineUniversity of CaliforniaSan Francisco

Personalised recommendations